HER2 staining intensity in HER2-positive disease: relationship with FISH amplification and clinical outcome in the HERA trial of adjuvant trastuzumab-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

HER2 staining intensity in HER2-positive disease: relationship with FISH amplification and clinical outcome in the HERA trial of adjuvant trastuzumab

Published:2013-11 Issue:11 Volume:24 Page:2761-2766
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Zabaglo L.,Stoss O.,Rüschoff J.,Zielinski D.,Salter J.,Arfi M.,Bradbury I.,Dafni U.,Piccart-Gebhart M.,Procter M.,Dowsett M.

Funder

Breakthrough Breast Cancer

NIHR Biomedical Research Centre at the Royal Marsden Hospital

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/24/11/2761/16700593/mdt275.pdf

Reference17 articles.

1. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer;Slamon;Science,1989

2. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer;Wolff;J Clin Oncol,2007

3. Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial;Dowsett;J Clin Oncol,2009

4. HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial;Perez;J Clin Oncol,2010

5. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer;Piccart-Gebhart;N Engl J Med,2005

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level;British Journal of Cancer;2023-09-22

2. Colloquium : Positronium physics and biomedical applications;Reviews of Modern Physics;2023-05-10

3. Assessment of Predictive Biomarkers in Breast Cancer: Challenges and Updates;Pathobiology;2022

4. Pathologic complete response to neoadjuvant anti-HER2 therapy is associated with HER2 immunohistochemistry score in HER2-positive early breast cancer;Medicine;2021-11-05

5. Differential prognostic value of positive HER2 status determined by immunohistochemistry or fluorescence in situ hybridization in breast cancer;Breast Cancer Research and Treatment;2020-07-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3